Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/2009

01-03-2009 | Original Article

Chordoma and chondrosarcoma gene profile: implications for immunotherapy

Authors: Joseph H. Schwab, Patrick J. Boland, Narasimhan P. Agaram, Nicholas D. Socci, Tianhua Guo, Gary C. O’Toole, Xinhui Wang, Elena Ostroumov, Christopher J. Hunter, Joel A. Block, Stephen Doty, Soldano Ferrone, John H. Healey, Cristina R. Antonescu

Published in: Cancer Immunology, Immunotherapy | Issue 3/2009

Login to get access

Abstract

Chordoma and chondrosarcoma are malignant bone tumors characterized by the abundant production of extracellular matrix. The resistance of these tumors to conventional therapeutic modalities has prompted us to delineate the gene expression profile of these two tumor types, with the expectation to identify potential molecular therapeutic targets. Furthermore the transcriptional profile of chordomas and chrondrosarcomas was compared to a wide variety of sarcomas as well as to that of normal tissues of similar lineage, to determine whether they express unique gene signatures among other tumors of mesenchymal origin, and to identify changes associated with malignant transformation. A HG-U133A Affymetrix Chip platform was used to determine the gene expression signature in 6 chordoma and 14 chondrosarcoma lesions. Validation of selected genes was performed by qPCR and immunohistochemistry (IHC) on an extended subset of tumors. By unsupervised clustering, chordoma and chondrosarcoma tumors grouped together in a genomic cluster distinct from that of other sarcoma types. They shared overexpression of many extracellular matrix genes including aggrecan, type II & X collagen, fibronectin, matrillin 3, high molecular weight-melanoma associated antigen (HMW-MAA), matrix metalloproteinase MMP-9, and MMP-19. In contrast, T Brachyury and CD24 were selectively expressed in chordomas, as were Keratin 8,13,15,18 and 19. Chondrosarcomas are distinguished by high expression of type IX and XI collagen. Because of its potential usefulness as a target for immunotherapy, the expression of HMW-MAA was analyzed by IHC and was detected in 62% of chordomas and 48% of chondrosarcomas, respectively. Furthermore, western blotting analysis showed that HMW-MAA synthesized by chordoma cell lines has a structure similar to that of the antigen synthesized by melanoma cells. In conclusion, chordomas and chondrosarcomas share a similar gene expression profile of up-regulated extracellular matrix genes. HMW-MAA represents a potential useful target to apply immunotherapy to these tumors.
Literature
1.
Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH, Maki RG, Socci ND, DeMatteo RP, Besmer P (2004) Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10:3282–3290PubMedCrossRef
2.
Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR (2007) Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13:170–181PubMedCrossRef
3.
Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom JM (2000) Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 88:2122–2134PubMedCrossRef
4.
Bertoni F, Bacchini P, Hogendoorn P (2002) Chondrosarcoma. IARC Press, Lyon
5.
Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B (1999) Sox9 is required for cartilage formation. Nat Genet 22:85–89PubMedCrossRef
6.
Bjornsson J, McLeod RA, Unni KK, Ilstrup DM, Pritchard DJ (1998) Primary chondrosarcoma of long bones and limb girdles. Cancer 83:2105–2119PubMedCrossRef
7.
Block JA, Inerot SE, Gitelis S, Kimura JH (1991) The effects of long term monolayer culture on the proteoglycan phenotype of a clonal population of mature human malignant chondrocytes. Connect Tissue Res 26: 295–313PubMedCrossRef
8.
Bos TJ, Margiotta P, Bush L, Wasilenko W (1999) Enhanced cell motility and invasion of chicken embryo fibroblasts in response to Jun over-expression. Int J Cancer 81:404–410PubMedCrossRef
9.
Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S (2004) Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 24:267–296PubMedCrossRef
10.
de Bri E, Reinholt FP, Heinegard D, Mengarelli-Widholm S, Norgard M, Svensson O (1996) Bone sialoprotein and osteopontin distribution at the osteocartilaginous interface. Clin Orthop Relat Res 330:251–260PubMedCrossRef
11.
Demircan K, Hirohata S, Nishida K, Hatipoglu OF, Oohashi T, Yonezawa T, Apte SS, Ninomiya Y (2005) ADAMTS-9 is synergistically induced by interleukin-1beta and tumor necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes. Arthritis Rheum 52:1451–1460PubMedCrossRef
12.
Eyre DR, Wu JJ, Fernandes RJ, Pietka TA, Weis MA (2002) Recent developments in cartilage research: matrix biology of the collagen II/IX/XI heterofibril network. Biochem Soc Trans 30:893–899PubMedCrossRef
13.
Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH (2005) Operative management of sacral chordoma. J Bone Joint Surg Am 87:2211–2216PubMedCrossRef
14.
Gitelis S, Bertoni F, Picci P, Campanacci M (1981) Chondrosarcoma of bone. The experience at the Istituto Ortopedico Rizzoli. J Bone Joint Surg Am 63:1248–1257PubMed
15.
Gottschalk D, Fehn M, Patt S, Saeger W, Kirchner T, Aigner T (2001) Matrix gene expression analysis and cellular phenotyping in chordoma reveals focal differentiation pattern of neoplastic cells mimicking nucleus pulposus development. Am J Pathol 158:1571–1578PubMed
16.
Healey JH, Lane JM (1986) Chondrosarcoma. Clin Orthop Relat Res:119–129
17.
Healey JH, Lane JM (1989) Chordoma: a critical review of diagnosis and treatment. Orthop Clin North Am 20:417–426PubMed
18.
Henderson SR, Guiliano D, Presneau N, McLean S, Frow R, Vujovic S, Anderson J, Sebire N, Whelan J, Athanasou N, Flanagan AM, Boshoff C (2005) A molecular map of mesenchymal tumors. Genome Biol 6:R76PubMedCrossRef
19.
Ishida T, Dorfman HD (1994) Chondroid chordoma versus low-grade chondrosarcoma of the base of the skull: can immunohistochemistry resolve the controversy? J Neurooncol 18:199–206PubMedCrossRef
20.
Kusama M, Kageshita T, Chen ZJ, Ferrone S (1989) Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol 143:3844–3852PubMed
21.
Lefebvre V, Huang W, Harley VR, Goodfellow PN, de Crombrugghe B (1997) SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol 17:2336–2346PubMed
22.
Luo W, Ko E, Hsu JC, Wang X, Ferrone S (2006) Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol 176:6046–6054PubMed
23.
Mirra J, Rocca C, Nelson S, Mertens F (2002) Notochordal tumours. IARC Press, Lyon
24.
Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89:466–470PubMedCrossRef
25.
Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S (1994) Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 54:415–421PubMed
26.
Naka T, Boltze C, Kuester D, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A (2004) Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma. Am J Clin Pathol 122:926–930PubMedCrossRef
27.
Ostroumov E, Hunter CJ (2007) The role of extracellular factors in human metastatic chordoma cell growth in vitro. Spine 32:2957–2964PubMed
28.
Overall CM, Kleifeld O (2006) Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227–239PubMedCrossRef
29.
Ozaki T, Hillmann A, Winkelmann W (1997) Surgical treatment of sacrococcygeal chordoma. J Surg Oncol 64:274–279PubMedCrossRef
30.
Ozanne BW, Spence HJ, McGarry LC, Hennigan RF (2007) Transcription factors control invasion: AP-1 the first among equals. Oncogene 26:1–10PubMedCrossRef
31.
Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J (2007) The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 13:2471–2478PubMedCrossRef
32.
Pei Y, Harvey A, Yu XP, Chandrasekhar S, Thirunavukkarasu K (2006) Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects. Osteoarthritis Cartilage 14:749–758PubMedCrossRef
33.
Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P (2004) Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 49:179–186PubMedCrossRef
34.
Pring ME, Weber KL, Unni KK, Sim FH (2001) Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am 83-A:1630–1642
35.
Rosenberg AE, Brown GA, Bhan AK, Lee JM (1994) Chondroid chordoma—a variant of chordoma. A morphologic and immunohistochemical study. Am J Clin Pathol 101:36–41PubMed
36.
Scott LA, Vass JK, Parkinson EK, Gillespie DA, Winnie JN, Ozanne BW (2004) Invasion of normal human fibroblasts induced by v-Fos is independent of proliferation, immortalization, and the tumor suppressors p16INK4a and p53. Mol Cell Biol 24:1540–1559PubMedCrossRef
37.
Segal NH, Pavlidis P, Antonescu CR, Maki RG, Noble WS, DeSantis D, Woodruff JM, Lewis JJ, Brennan MF, Houghton AN, Cordon-Cardo C (2003) Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 163:691–700PubMed
38.
Sekiya I, Tsuji K, Koopman P, Watanabe H, Yamada Y, Shinomiya K, Nifuji A, Noda M (2000) SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem 275:10738–10744PubMedCrossRef
39.
Sundaresan N, Galicich JH, Chu FC, Huvos AG (1979) Spinal chordomas. J Neurosurg 50:312–319PubMed
40.
Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S (1989) Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 8:85–95PubMed
41.
Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, De Maglio G, den Bakker MA, Di Francesco L, Kalil RK, Athanasou NA, O’Donnell P, McCarthy EF, Flanagan AM (2008) Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol 32(4):572–580PubMedCrossRef
42.
Uria JA, Balbin M, Lopez JM, Alvarez J, Vizoso F, Takigawa M, Lopez-Otin C (1998) Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol 153:91–101PubMed
43.
Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, Boshoff C, Flanagan AM (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209:157–165PubMedCrossRef
44.
Wagener R, Ehlen HW, Ko YP, Kobbe B, Mann HH, Sengle G, Paulsson M (2005) The matrilins-adaptor proteins in the extracellular matrix. FEBS Lett 579:3323–3329PubMedCrossRef
45.
Xie WF, Zhang X, Sakano S, Lefebvre V, Sandell LJ (1999) Trans-activation of the mouse cartilage-derived retinoic acid-sensitive protein gene by Sox9. J Bone Miner Res 14:757–763PubMedCrossRef
46.
Zharkikh A, Li WH (1995) Estimation of confidence in phylogeny: the complete-and-partial bootstrap technique. Mol Phylogenet Evol 4:44–63PubMedCrossRef
Metadata
Title
Chordoma and chondrosarcoma gene profile: implications for immunotherapy
Authors
Joseph H. Schwab
Patrick J. Boland
Narasimhan P. Agaram
Nicholas D. Socci
Tianhua Guo
Gary C. O’Toole
Xinhui Wang
Elena Ostroumov
Christopher J. Hunter
Joel A. Block
Stephen Doty
Soldano Ferrone
John H. Healey
Cristina R. Antonescu
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-008-0557-7

Other articles of this Issue 3/2009

Cancer Immunology, Immunotherapy 3/2009 Go to the issue

Review

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

Original Article

A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy

Original Article

Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding β2-microglobulin genes

Short Communication

Potential immunologic effects of statins in cancer following transplantation

Original Article

Generation of a human IgM monoclonal antibody directed against HLA class II molecules: a potential agent in the treatment of haematological malignancies

Original Article

Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits